Table 1.
Baseline characteristics for all analysed patients and by MDA achievement at month 6
| Baseline characteristic | All patients (N = 1684) | MDA achievement at month 6 | |
|---|---|---|---|
| Yes (n = 597) | No (n = 1087) | ||
| Female sex, % | 50.6 | 39.3 | 56.8 |
| Age, years | 50.0 (11.5) | 46.7 (11.9) | 51.8 (10.9) |
| BMI, kg/m2 | 28.6 (5.6) | 27.4 (5.0) | 29.3 (5.7) |
| Duration of arthritis symptoms, years | 9.5 (8.6) | 9.0 (8.3) | 9.7 (8.8) |
| Duration of psoriasis symptoms, years | 18.1 (13.2) | 17.1 (11.9) | 18.6 (13.8) |
| DAS28 | 5.06 (1.08) | 4.80 (1.01) | 5.21 (1.09) |
| Tender joint count (78 joints) | 16.3 (15.4) | 12.2 (12.0) | 18.5 (16.6) |
| Swollen joint count (76 joints) | 9.3 (10.9) | 7.8 (8.8) | 10.1 (11.9) |
| Paina | 6.3 (2.1) | 5.5 (2.3) | 6.7 (1.9) |
| PGAa | 7.0 (1.6) | 6.7 (1.7) | 7.1 (1.6) |
| Function (% remaining)b | 67.6 (21.0) | 78.3 (17.5) | 61.7 (20.5) |
| Body surface area of psoriasis, percentage of patients | |||
| <3% | 34.4 | 38.5 | 32.2 |
| 3–10% | 33.2 | 31.0 | 34.4 |
| 11–20% | 16.4 | 16.0 | 16.6 |
| >20% | 16.0 | 14.5 | 16.8 |
| Dactylitis, percentage of patients | 48.0 | 47.7 | 48.2 |
| Enthesitis, percentage of patients | 27.3 | 23.6 | 29.3 |
| Number of previous biologic therapies, percentage of of patients | |||
| 0 | 82.1 | 87.9 | 78.8 |
| 1 | 15.4 | 10.6 | 18.0 |
| 2 or 3 | 2.6 | 1.5 | 3.1 |
Results are presented as mean (s.d.) unless otherwise indicated.
a
Measured on a scale from 0 (none) to 10 (severe).
b
As assessed by FFbH on a scale of 0 (total loss of functional capacity) to 100 (maximal functional capacity). FFbH: Funktionsfragebogen Hannover; MDA: minimal disease activity; PGA: patient global disease activity assessment.